Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Theraprofen** is a prescription co-packaged oral product developed by Targeted Medical Pharma and marketed through Physician Therapeutics. It contains ibuprofen tablets, a nonsteroidal anti-inflammatory drug, together with Theramine capsules, a proprietary medical food intended for dietary management of metabolic processes associated with pain disorders and inflammatory conditions. Ibuprofen provides analgesic and anti-inflammatory activity through reversible, nonselective inhibition of cyclooxygenase enzymes and consequent reduction of prostaglandin synthesis; Theramine is intended to provide nutritional support for pain-related metabolic and neurotransmitter pathways. Theraprofen was evaluated in a Phase 4 randomized, double-blind study in chronic low back pain. The product was listed in DailyMed as an unapproved drug product. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b720c99f-feaa-4453-ba4a-c3377501f7b8))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Theraprofen.